Executive interview – Laboratorios Farmacéuticos ROVI

ROVI is a profitable speciality healthcare company that markets ~40 proprietary and in-licensed products across nine core franchises, mainly in its domestic Spanish market. Since obtaining market authorisation for its internally developed enoxaparin biosimilar (Becat) in multiple countries, ROVI has commenced marketing in several European countries and has signed out-licensing agreements that cover 91 countries globally – key drivers for sales and operating growth in the medium term. In September 2019, ROVI announced that it plans to build a new low molecular weight heparin (LMWH) manufacturing facility over the next three years, doubling its current capacity. R&D progress continues with its proprietary ISM technology. Following positive PRISMA-3 data on DORIA (risperidone ISM), a long-acting injectable for schizophrenia, regulatory filings can be expected during 2020.

Laboratorios Farmacéuticos ROVI is a fully integrated Spanish speciality pharmaceutical company involved in the development, in-licensing, manufacture and marketing of small molecule and speciality biologic drugs with a particular expertise in LMWH.